Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma

NCT03269552 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03269552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03269552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
December 18, 2017
Completion date
December 28, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma, recurrent marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory marginal zone lymphoma, refractory waldenstrom macroglobulinemia, waldenstrom macroglobulinemia